Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2020-10-15 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-10-15 English
10-Q
Interim / Quarterly Report Q1 2021
2020-10-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text includes an Item 2.02 about Results of Operations and Financial Condition, referencing a press release with quarterly financial results, and Item 5.02 about a grant of performance-based restricted stock units to the CEO, which is a management compensation update. The document does not contain full financial statements or detailed financial analysis itself but rather announces events and includes a press release as an exhibit. It also includes a signature section typical of regulatory filings. Given the nature of the content—announcing financial results and management compensation changes—and the form type (8-K), this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. It is not an Earnings Release (ER) because it is a formal SEC filing, not just a press release, and it is not a Management Report (MDA) or Annual/Interim Report (10-K or IR) because it lacks comprehensive financial data. The document also includes management information but primarily focuses on the announcement of events rather than detailed board changes, so MANG is less fitting. Therefore, the best classification is Regulatory Filings (RNS).
2020-10-06 English
FORM 4
Director's Dealing
2020-10-02 English
DEF 14A
Proxy Solicitation & Information Statement
2020-08-31 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the entry into a definitive agreement to sell a manufacturing facility, which is a material event. The document includes a press release as an exhibit and does not contain detailed financial statements or comprehensive financial analysis. It is not an annual or quarterly report, nor is it a transcript or proxy statement. The nature of the announcement relates to a significant transaction or asset sale, which fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and is a standalone announcement of a material event, not a full report. Therefore, the classification is CAP with high confidence.
2020-08-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.